Kidney Cancer Clinical Trials in Georgia

Cancer Type = Kidney Cancer

Cancer Type = Kidney Cancer

There are currently 20 active Kidney Cancer clinical trials in Georgia.
1.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
2.
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma
NCI ID
NCT02983045
Protocol IDs
16-214-02
NCI-2017-00053
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04022343
Protocol IDs
Winship4643-19
NCI-2019-02253
IRB00110583
6.
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03397394
Protocol IDs
CO-338-085
NCI-2018-01112
10.
NCORP Trial
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Cancer Type
Kidney Cancer
NCI ID
NCT03055013
Protocol IDs
EA8143
NCI-2016-00326
Treatment Sites (2)
11.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
14.
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer
NCI ID
NCT02567409
Protocol IDs
9947
NCI-2015-01642
PHII-135
16.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
17.
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Cancer Type
Ewing Sarcoma, Kidney Cancer, Unknown Primary
NCI ID
NCT02867592
Protocol IDs
ADVL1622
NCI-2016-01258
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
18.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
19.
Phase II Study of Front Line Therapy with Nivolumab and Salvage Nivolumab + Ipilimumab in Patients with Advanced Renal Cell Carcinoma
Cancer Type
Kidney Cancer
NCI ID
NCT03117309
Protocol IDs
2017-0010
NCI-2017-02166
GU16-260
CA209-669
20.
Study of Renal Tumors in Pediatric Patients
Cancer Type
Kidney Cancer
NCI ID
NCT00898365
Protocol IDs
COG-AREN03B2
AREN03B2
Treatment Sites (4)
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.